Please Wait...

Quality Assurance

Bioclinica Laboratory is committed to providing clients with reliable and reproducible analytical methods for biomarkers while safeguarding patient care and achieving the highest standards in laboratory quality. Using a convergence of analytic pre-study and in-study validation across a wide range of assay formats, we deliver biomarker feasibility assessments and evaluation in a regulatory compliant environment. Our rigorous quality control combined with our experienced laboratory services translates into efficient analysis of biological samples from your clinical trials. All of Bioclinica Lab's procedures and training programs comply with current regulatory requirements.

Our key business operations are governed by a comprehensive Quality Management System implemented to reflect industry standards and best practices for study management, software development, IT infrastructure management, documentation, QC assessments, training, and CAPA.

The Molecular Markers Database System (MMDS)
The Molecular Markers Database System (MMDS) was developed by Bioclinica Lab for handling clinical trial data, from sample information through data analysis and transfer. The MMDS, based on an Oracle database and fully 21 CFR Part 11 compliant, supports each new study and provides a consistent user interface, regardless of the size or complexity of the clinical protocol. It has components for study team members to perform protocol information entry, sample receipt, data query, analysis, reporting, and other functions related to study data. Our analytical instruments and automated platforms are connected to the MMDS, and our data security procedures assure integrity, protection and backup of study data. Bioclinica Lab has a dedicated IT department that is responsible for the development, improvement, maintenance and validation of the MMDS.

As part of validation and QC, Bioclinica Lab regularly participates in Proficiency Testing of molecular markers by the College of American Pathologists (CAP) and the UK National External Quality Assessment Service (UK NEQAS). We continuously monitor and improve our quality to be in compliance with current regulatory guidelines.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great advice from our Dir. Cardiovascular Imaging on how to achieve top quality imaging acquisitions & assessments… https://t.co/P57970FrOf
bioclinica (16 hours ago)
RT @CenterWatch: #CWWeekly: The increasing trend of adopting digital health and #mhealth apps for patient care. Read more, https://t.co/wo9…
bioclinica (17 hours ago)
RT @CenterWatch: Examining the difference between #patient engagement & patient recruitment. Read more in #CWPulse by @AshleyTointon, https…
bioclinica (17 hours ago)
RT @CenterWatch: How can #socialmedia play a role in health disparities and #clinicaltrial patient recruitment? Read more in #CWPulse by @A…
bioclinica (17 hours ago)
RT @RAPSorg: What New @FDAcdrhIndustry Guidance is Coming in FY 2018: Alternative 510(k) Pathway and More | #Regulatory Recon https://t.co/…
bioclinica (17 hours ago)
RT @RAPSorg: .@US_FDA Finalizes Guidance on Promotional Drug Labeling and Ads | #Regulatory Focus https://t.co/2rmtTWajlf #FDA #pharma
bioclinica (17 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices